Hostname: page-component-7b9c58cd5d-bslzr Total loading time: 0.001 Render date: 2025-03-15T16:01:45.601Z Has data issue: false hasContentIssue false

Peroxisome proliferator-activated receptor gamma co-activator-1 alpha in depression and the response to electroconvulsive therapy

Published online by Cambridge University Press:  07 September 2018

Karen M. Ryan
Affiliation:
Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland Department of Psychiatry, St. Patrick's University Hospital, Trinity College Dublin, Dublin, Ireland
Ian Patterson
Affiliation:
Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
Declan M. McLoughlin*
Affiliation:
Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland Department of Psychiatry, St. Patrick's University Hospital, Trinity College Dublin, Dublin, Ireland
*
Author for correspondence: Declan M. McLoughlin, E-mail: d.mcloughlin@tcd.ie
Rights & Permissions [Opens in a new window]

Abstract

Background

The transcriptional coactivator peroxisome proliferator-activated receptor-γ coactivator (PGC-1α), termed the ‘master regulator of mitochondrial biogenesis’, has been implicated in stress and resilience to stress-induced depressive-like behaviours in animal models. However, there has been no study conducted to date to examine PGC-1α levels in patients with depression or in response to antidepressant treatment. Our aim was to assess PGC-1α mRNA levels in blood from healthy controls and patients with depression pre-/post-electroconvulsive therapy (ECT), and to examine the relationship between blood PGC-1α mRNA levels and clinical symptoms and outcomes with ECT.

Methods

Whole blood PGC-1α mRNA levels were analysed in samples from 67 patients with a major depressive episode and 70 healthy controls, and in patient samples following a course of ECT using quantitative real-time polymerase chain reaction (qRT-PCR). Exploratory subgroup correlational analyses were carried out to determine the relationship between PGC-1α and mood scores.

Results

PGC-1α levels were lower in patients with depression compared with healthy controls (p = 0.03). This lower level was predominantly accounted for by patients with psychotic unipolar depression (p = 0.004). ECT did not alter PGC-1α levels in the depressed group as a whole, though exploratory analyses revealed a significant increase in PGC-1α in patients with psychotic unipolar depression post-ECT (p = 0.045). We found no relationship between PGC-1α mRNA levels and depression severity or the clinical response to ECT.

Conclusions

PGC-1α may represent a novel therapeutic target for the treatment of depression, and be a common link between various pathophysiological processes implicated in depression.

Type
Original Articles
Copyright
Copyright © Cambridge University Press 2018 

Introduction

Over 4.4% of the global population live with depression (Friedrich, Reference Friedrich2017; World Health Organisation, 2017), which ranked as the leading cause of disability worldwide in 2017 (World Health Organisation, 2017). For many years, the monoamine hypothesis of depression prevailed (Coppen, Reference Coppen1967). However, one of the more recent hypotheses put forward is the ‘mitochondrial psychiatry’ model of depression (Gardner and Boles, Reference Gardner and Boles2011), which postulates that impaired mitochondrial bioenergetics functions in the development of depressive episodes (Klinedinst and Regenold, Reference Klinedinst and Regenold2015). Indeed, mitochondrial abnormalities, increased oxidative stress and brain metabolism changes are often observed in patients with depression (Karabatsiakis et al., Reference Karabatsiakis, Bock, Salinas-Manrique, Kolassa, Calzia, Dietrich and Kolassa2014; Chang et al., Reference Chang, Jou, Lin, Lai and Liu2015; Wang and Dwivedi, Reference Wang and Dwivedi2017).

The transcriptional coactivator peroxisome proliferator-activated receptor-γ coactivator (PGC-1α) regulates cellular energy production (Villena, Reference Villena2015), and is termed ‘master regulator of mitochondrial biogenesis’ (Fernandez-Marcos and Auwerx, Reference Fernandez-Marcos and Auwerx2011). PGC-1α was first identified as a cold-inducible peroxisome proliferator-activated receptor gamma (PPAR-γ) co-activator in brown adipose tissue (Puigserver et al., Reference Puigserver, Wu, Park, Graves, Wright and Spiegelman1998). It is also induced by caloric restriction and exercise (Rodgers et al., Reference Rodgers, Lerin, Haas, Gygi, Spiegelman and Puigserver2005; Agudelo et al., Reference Agudelo, Femenia, Orhan, Porsmyr-Palmertz, Goiny, Martinez-Redondo, Correia, Izadi, Bhat, Schuppe-Koistinen, Pettersson, Ferreira, Krook, Barres, Zierath, Erhardt, Lindskog and Ruas2014), all of which require energy expenditure. The PGC-1α gene, also known as PPARGC1A, maps to chromosome 4p15.1 (Esterbauer et al., Reference Esterbauer, Oberkofler, Krempler and Patsch1999), and encodes a 798 amino acid protein (Liang and Ward, Reference Liang and Ward2006). The 4p15–4p16 region has previously been linked to neuropsychiatric conditions, such as bipolar disorder and schizophrenia (Blackwood et al., Reference Blackwood, He, Morris, McLean, Whitton, Thomson, Walker, Woodburn, Sharp, Wright, Shibasaki, St Clair, Porteous and Muir1996; Als et al., Reference Als, Dahl, Flint, Wang, Vang, Mors, Kruse and Ewald2004; Christoforou et al., Reference Christoforou, Le Hellard, Thomson, Morris, Tenesa, Pickard, Wray, Muir, Blackwood, Porteous and Evans2007). PGC-1α has diverse functions and plays a role in gluconeogenesis and glucose homeostasis, glycogenolysis, fatty acid oxidation, reactive oxygen species (ROS) suppression, mitochondrial biogenesis and respiration and oxidative phosphorylation (Vega et al., Reference Vega, Huss and Kelly2000; Mootha et al., Reference Mootha, Lindgren, Eriksson, Subramanian, Sihag, Lehar, Puigserver, Carlsson, Ridderstrale, Laurila, Houstis, Daly, Patterson, Mesirov, Golub, Tamayo, Spiegelman, Lander, Hirschhorn, Altshuler and Groop2003; Lin et al., Reference Lin, Wu, Tarr, Lindenberg, St-Pierre, Zhang, Mootha, Jager, Vianna, Reznick, Cui, Manieri, Donovan, Wu, Cooper, Fan, Rohas, Zavacki, Cinti, Shulman, Lowell, Krainc and Spiegelman2004; St-Pierre et al., Reference St-Pierre, Drori, Uldry, Silvaggi, Rhee, Jager, Handschin, Zheng, Lin, Yang, Simon, Bachoo and Spiegelman2006; Kim et al., Reference Kim, Koh, Higashida, Jung, Holloszy and Han2015). It is implicated in the direct co-activation of various transcription factors, e.g. PPARs (Puigserver et al., Reference Puigserver, Wu, Park, Graves, Wright and Spiegelman1998; Vega et al., Reference Vega, Huss and Kelly2000), thyroid hormone receptors (Puigserver et al., Reference Puigserver, Wu, Park, Graves, Wright and Spiegelman1998), glucocorticoid receptors (Jang et al., Reference Jang, Kim, Park, Park, Choi, Kim, Kim, Kim, Lee and Lee2007), oestrogen-related receptors (Takacs et al., Reference Takacs, Petoukhov, Atkinson, Roblin, Ogi, Demeler, Potier, Chebaro, Dejaegere, Svergun, Moras and Billas2013) and the forkhead O-box (FOXO) family (Puigserver et al., Reference Puigserver, Rhee, Donovan, Walkey, Yoon, Oriente, Kitamura, Altomonte, Dong, Accili and Spiegelman2003). PGC-1α function can be influenced by post-transcriptional modifications, including phosphorylation, acetylation, SUMOylation and methylation (Rytinki and Palvimo, Reference Rytinki and Palvimo2009; Sugden et al., Reference Sugden, Caton and Holness2010). It is highly expressed in tissues with a high energy demand, including brain, liver, lung and skeletal muscle (Soyal et al., Reference Soyal, Felder, Auer, Hahne, Oberkofler, Witting, Paulmichl, Landwehrmeyer, Weydt and Patsch2012; Jiang et al., Reference Jiang, Kang, Zhang, Karuppagounder, Xu, Lee, Kang, Lee, Zhang, Pletnikova, Troncoso, Pirooznia, Andrabi, Dawson and Dawson2016). In the brain, PGC-1α is found in the cortex, hippocampus and cerebellum (Tritos et al., Reference Tritos, Mastaitis, Kokkotou, Puigserver, Spiegelman and Maratos-Flier2003), and is expressed in neurons (Lin et al., Reference Lin, Wu, Tarr, Lindenberg, St-Pierre, Zhang, Mootha, Jager, Vianna, Reznick, Cui, Manieri, Donovan, Wu, Cooper, Fan, Rohas, Zavacki, Cinti, Shulman, Lowell, Krainc and Spiegelman2004), astrocytes (Nijland et al., Reference Nijland, Witte, van het Hof, van der Pol, Bauer, Lassmann, van der Valk, de Vries and van Horssen2014; Aguirre-Rueda et al., Reference Aguirre-Rueda, Guerra-Ojeda, Aldasoro, Iradi, Obrador, Ortega, Mauricio, Vila and Valles2015) and microglia (Labuzek et al., Reference Labuzek, Liber, Gabryel and Okopien2010). It is highly expressed in GABAergic (gamma-aminobutyric acid) cells (Cowell et al., Reference Cowell, Blake and Russell2007) and, in mice, is required for normal inhibitory neurotransmission and synaptic function (Dougherty et al., Reference Dougherty, Bartley, Lucas, Hablitz, Dobrunz and Cowell2014).

PGC-1α has been implicated in several neurodegenerative disorders, such as Alzheimer's disease, Huntington's disease, Parkinson's disease and amyotrophic lateral sclerosis (Qin et al., Reference Qin, Haroutunian, Katsel, Cardozo, Ho, Buxbaum and Pasinetti2009; Clark et al., Reference Clark, Reddy, Zheng, Betensky and Simon2011; Thau et al., Reference Thau, Knippenberg, Korner, Rath, Dengler and Petri2012; Weydt et al., Reference Weydt, Soyal, Landwehrmeyer and Patsch2014) and also in depression (Nierenberg et al., Reference Nierenberg, Ghaznavi, Mathias, Ellard, Janos and Sylvia2018). In this regard, an association was found between a single nucleotide polymorphism in the PGC-1α/PPARGC1A gene and major depressive disorder in a sample of 974 Caucasian individuals, though this did not survive multiple testing correction and was not replicated in a second sample set (Schosser et al., Reference Schosser, Gaysina, Cohen-Woods, Domenici, Perry, Tozzi, Korszun, Gunasinghe, Gray, Jones, Binder, Holsboer, Craddock, Owen, Craig, Farmer, Muglia and McGuffin2011). In animal models, PGC-1α has been implicated in stress and the resilience to stress-induced depressive-like behaviours (Khalaj et al., Reference Khalaj, Nejad, Mohammadi, Zadeh, Pour, Ahmadiani, Khodagholi, Ashabi, Alamdary and Samami2013; Agudelo et al., Reference Agudelo, Femenia, Orhan, Porsmyr-Palmertz, Goiny, Martinez-Redondo, Correia, Izadi, Bhat, Schuppe-Koistinen, Pettersson, Ferreira, Krook, Barres, Zierath, Erhardt, Lindskog and Ruas2014; Glombik et al., Reference Glombik, Stachowicz, Slusarczyk, Trojan, Budziszewska, Suski, Kubera, Lason, Wedzony, Olszanecki and Basta-Kaim2015). Prenatal stress induces depressive-like behaviours in rats, which is accompanied by reduced PGC-1α mRNA levels in frontal cortex and hippocampus (Glombik et al., Reference Glombik, Stachowicz, Slusarczyk, Trojan, Budziszewska, Suski, Kubera, Lason, Wedzony, Olszanecki and Basta-Kaim2015). PGC-1α protein is also increased in rat hippocampus following acute restraint stress (Khalaj et al., Reference Khalaj, Nejad, Mohammadi, Zadeh, Pour, Ahmadiani, Khodagholi, Ashabi, Alamdary and Samami2013). Skeletal muscle-specific PGC-1α transgenic mice are resilient to chronic mild stress-induced depressive-like behaviours, but muscle-specific PGC-1α knock-out mice display depressive-like behaviours (Agudelo et al., Reference Agudelo, Femenia, Orhan, Porsmyr-Palmertz, Goiny, Martinez-Redondo, Correia, Izadi, Bhat, Schuppe-Koistinen, Pettersson, Ferreira, Krook, Barres, Zierath, Erhardt, Lindskog and Ruas2014). The resilience of mice overexpressing PGC-1α to chronic stress may occur owing to effects of PGC-1α on the kynurenine pathway, the main pathway involved in peripheral metabolism of the amino acid tryptophan (Muller and Schwarz, Reference Muller and Schwarz2007). Mice overexpressing PGC-1α show increased peripheral expression of kynurenine aminotransferases (KATs) and enhanced peripheral metabolism of kynurenine to kynurenic acid (Agudelo et al., Reference Agudelo, Femenia, Orhan, Porsmyr-Palmertz, Goiny, Martinez-Redondo, Correia, Izadi, Bhat, Schuppe-Koistinen, Pettersson, Ferreira, Krook, Barres, Zierath, Erhardt, Lindskog and Ruas2014), which may limit the levels of kynurenine available to the brain where it could be converted to metabolites like quinolinic acid, leading to detrimental effects on neurotransmission and behaviour (Muller and Schwarz, Reference Muller and Schwarz2007; Harkin, Reference Harkin2014). Additionally, mice overexpressing PGC-1α show no changes in hippocampal neurotrophins, e.g. brain-derived neurotrophic factor (BDNF), glial cell-line-derived neurotrophic factor (GDNF), or vascular endothelial growth factor A/B (VEGFA/B), astrocytic glial fibrillary acidic protein (GFAP), or structural synaptic genes, following exposure to chronic mild stress, all of which show alterations in patients with depression (Kang et al., Reference Kang, Voleti, Hajszan, Rajkowska, Stockmeier, Licznerski, Lepack, Majik, Jeong, Banasr, Son and Duman2012; Carvalho et al., Reference Carvalho, Kohler, McIntyre, Knochel, Brunoni, Thase, Quevedo, Fernandes and Berk2015; Lin and Tseng, Reference Lin and Tseng2015; Polyakova et al., Reference Polyakova, Schroeter, Elzinga, Holiga, Schoenknecht, de Kloet and Molendijk2015; Tseng et al., Reference Tseng, Cheng, Chen, Wu and Lin2015; Cobb et al., Reference Cobb, O'Neill, Milner, Mahajan, Lawrence, May, Miguel-Hidalgo, Rajkowska and Stockmeier2016). Thus, PGC-1α may be protective against stress-induced changes in synaptic transmission and plasticity, and therefore play a key role in depression and response to antidepressant therapies.

Electroconvulsive therapy (ECT) is the most acutely effective antidepressant treatment available for severe, treatment-resistant and sometimes life-threatening depressive episodes (UK ECT Review Group, 2003; Berlim et al., Reference Berlim, Van den Eynde and Daskalakis2013). However, despite being in use for 80 years, its molecular mechanism of action remains unclear. Electroconvulsive stimulation (ECS), the animal model equivalent of ECT, has provided insights into the molecular mechanisms of ECT (Duman and Vaidya, Reference Duman and Vaidya1998; Kato, Reference Kato2009). Interestingly, ECS has been shown to increase mitochondrial activity in rat brain (Burigo et al., Reference Burigo, Roza, Bassani, Fagundes, Rezin, Feier, Dal-Pizzol, Quevedo and Streck2006).

PGC-1α mRNA levels have thus far not been reported in patients with depression. Our aims therefore were to determine if whole blood PGC-1α mRNA levels differ between patients with severe depression and healthy controls, and to assess whether treatment with a course of ECT affects PGC-1α levels. We also performed exploratory analyses to examine PGC-1α levels in subgroups of patients with depression and to determine whether there is any relationship between PGC-1α mRNA levels and mood and response to ECT.

Materials and methods

Participants and blood collection

Patients with severe depression were recruited as part of the enhancing the effectiveness of electroconvulsive therapy in severe depression (EFFECT-Dep; ISRCTN23577151) trial, a pragmatic, patient- and rater-blinded, non-inferiority trial for patients with major depression that compared the effects of twice-weekly moderate-dose bitemporal (1.5× seizure threshold) and high-dose unilateral (6× seizure threshold) ECT (Semkovska et al., Reference Semkovska, Landau, Dunne, Kolshus, Kavanagh, Jelovac, Noone, Carton, Lambe, McHugh and McLoughlin2016). Recruitment was between 2008 and 2012 in St. Patrick's Mental Health Services, an independent non-profit organization that runs Ireland's largest ECT clinic (http://www.stpatricks.ie/). Patients who met diagnostic criteria for a major depressive episode were recruited and randomly allocated to a treatment group prior to their first ECT session. Inclusion criteria were: >18 years old, referred for ECT to treat a major depressive episode as diagnosed by the Structured Clinical Interview for DSM-IV Axis I Disorders (First et al., Reference First, Spitzer, Gibbon and Williams1996) and pre-treatment Hamilton Depression Rating Scale 24-item version (HAM-D24) score ⩾21 (Beckham and Leber, Reference Beckham and Leber1985). Exclusion criteria were: substance misuse in the previous 6 months, unfit for general anaesthesia, ECT in the previous 6 months, dementia or other axis I diagnosis, involuntary status or inability/refusal to consent. The study was performed in accordance with the Declaration of Helsinki (World Medical Association, 2013) and approved by St Patrick's University Hospital Research Ethics Committee. All participants provided written informed consent.

Fasting peripheral blood samples were taken 07:30–09:30 on the morning of the first ECT treatment and 1–3 days following ECT completion. Blood (2.5 mL) was collected into PAXgene© Blood RNA tubes (PreAnalytiX, Qiagen Ltd., Ireland) as per manufacturer's guidelines. Samples were stored at room temperature for 24 h, then at −20 °C for 24 h, followed by storage at −80 °C.

Healthy controls were recruited via local newspapers and social media. Fasting control blood samples were taken 07:30–09:30 on assessment days.

Participants with type I or type II diabetes, chronic immune disorders or major neurological illnesses (e.g. Parkinson's disease and stroke) were excluded from molecular analyses as alterations in PGC-1α have been detected in these conditions (Mootha et al., Reference Mootha, Lindgren, Eriksson, Subramanian, Sihag, Lehar, Puigserver, Carlsson, Ridderstrale, Laurila, Houstis, Daly, Patterson, Mesirov, Golub, Tamayo, Spiegelman, Lander, Hirschhorn, Altshuler and Groop2003; Kim et al., Reference Kim, Sweeney, Shigenaga, Chui, Moser, Grunfeld and Feingold2007; Clark et al., Reference Clark, Reddy, Zheng, Betensky and Simon2011; Nierenberg et al., Reference Nierenberg, Ghaznavi, Mathias, Ellard, Janos and Sylvia2018).

ECT and clinical assessments

ECT was administered twice-weekly with hand-held electrodes, using methohexitone (0.75–1.0 mg/kg) for anaesthesia and succinylcholine (0.5–1.0 mg/kg) as the muscle relaxant (Semkovska et al., Reference Semkovska, Landau, Dunne, Kolshus, Kavanagh, Jelovac, Noone, Carton, Lambe, McHugh and McLoughlin2016). Patients were maintained on their usual medications during the course of ECT.

Demographic and clinical data were documented. Depression severity and response to ECT were assessed using the HAM-D24. Response was defined as ⩾60% reduction in HAM-D24 score and a score ⩽16 at the end of treatment. Remission was defined as ⩾60% reduction in the HAM-D24 score and a score ⩽10 for 2 weeks.

Quantitative real-time polymerase chain reaction (qRT-PCR)

Whole blood mRNA was extracted using a PAXgene Blood RNA kit (PreAnalytix). Following reverse transcription using a high capacity cDNA archive kit (Applied Biosystems, UK), mRNA levels were assessed using qRT-PCR on a StepOnePlus™ instrument (Applied Biosystems) using TaqMan® Gene Expression Assays and TaqMan® Fast Advanced Master Mix (Applied Biosystems). Briefly, a master mix was made by combining 5 µL of TaqMan Fast Advanced Master Mix with 0.5 µL of the target primer (PGC1α, Hs00173304_m1) and 0.5 µL of the endogenous control (glyceraldehyde 3-phosphate dehydrogenase; GAPDH) primer (Hs02758991_g1). The master mix (6 µL) was added to each well of the PCR plates along with cDNA (4 µL), plated in duplicate. The cycling conditions consisted of an initial polymerase activation step of 95 °C for 20 s followed by 50 cycles of 95 °C for 1 s and 60 °C for 20 s. Relative quantification (RQ) levels were calculated using the comparative CT method (Livak and Schmittgen, Reference Livak and Schmittgen2001) after normalization to GAPDH. Interplate calibrators were included on each plate to compensate for the variation across qRT-PCR runs, which was accounted for using qBase+ software, version 3.1 (Biogazelle, Belgium; http://www.qbaseplus.com).

Statistical analysis

Statistical analyses were carried out using SPSS, version 21 (IBM Corporation, USA). All data were tested for normality using Q–Q plots and Shapiro–Wilk tests, and log-transformed where necessary. Baseline clinical and demographic characteristics are presented as means with standard deviations (s.d.) or number (%) per group where appropriate. Categorical data were analysed using Chi-square (χ2) tests.

Data were analysed using general linear models. We adjusted for potential variance owing to body mass index (BMI; kg/m2) and smoking, which have previously been associated with PGC-1α and mood (Kendler et al., Reference Kendler, Neale, MacLean, Heath, Eaves and Kessler1993; Simon et al., Reference Simon, Von Korff, Saunders, Miglioretti, Crane, van Belle and Kessler2006; Tang et al., Reference Tang, Wagner and Breen2010; Sajan et al., Reference Sajan, Ivey and Farese2015). Smoking status was dichotomized into current v. non-smoker. We also adjusted for age and sex. Correlational analyses were carried out using either Pearson's product-moment correlation coefficient (Pearson's r) or Spearman's rank correlation coefficient ρ (Spearman's ρ). For pre-/post-ECT analyses, we included polarity, depression severity at baseline, presence of psychosis and electrode placement as covariates where appropriate. Differences with a p value <0.05 were deemed statistically significant. For exploratory subgroup correlation analyses, a p value <0.01 was deemed statistically significant to account for multiple comparisons.

Results

Participants

Of the 138 patients with depression recruited into the EFFECT-Dep trial, samples for mRNA extraction and PGC-1α qRT-PCR were available for 83 people. Of these, 16 samples were omitted as participants met exclusion criteria for molecular analyses listed above (diabetes, n = 9; systemic lupus erythematosus, n = 1; Parkinson's disease, n = 3; stroke, n = 3). Thus, we included 70 healthy controls and 67 patients in our final analyses.

Demographic and clinical data for both controls and patients are summarized in Table 1. The groups were balanced for age and sex. While profession significantly differed between the groups (p = 0.002), it was not included as a covariate as we found no association between profession and PGC-1α levels (p > 0.05).

Table 1. Demographic and clinical characteristics of participants

BMI, body mass index; ECT, electroconvulsive therapy; HAM-D24, Hamilton depression rating scale, 24-item version; MAOI, monoamine oxidase inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.

Data are presented as means with standard deviations (s.d.) or number (%) per group where appropriate.

PGC-1α mRNA levels are lower in patients with depression compared with healthy controls

PGC-1α mRNA RQ data were log-transformed as they initially failed tests for normality, but were normal following log transformation. PGC-1α mRNA levels in patients with depression (n = 67) were initially compared with those of healthy controls (n = 70) without adjustment. PGC-1α levels were significantly lower (F 1,135 = 4.65, p = 0.03) in patients with depression at baseline (pre-ECT) compared with controls (Fig. 1). Adjusting for potential covariates (age, sex, BMI and smoking) did not alter this result (F 1,131 = 4.01, p = 0.047).

Fig. 1. PGC-1α mRNA levels are lower in patients with depression compared with controls but are unaltered by ECT. PGC-1α mRNA levels were significantly lower in patients with depression at baseline, i.e. pre-ECT (n = 67), compared with controls (n = 70). PGC-1α mRNA levels were unaltered in patients with depression following treatment with ECT. Data are expressed as unadjusted mean log10RQ ± s.e.m.. *p < 0.05 v. control.

We subsequently compared PGC-1α levels in patients with unipolar or bipolar depression to those of age- and sex-matched controls (unipolar depressed v. controls: age, t = 1.19, p = 0.24; sex, χ2 = 0.08, p = 0.78; bipolar depressed v. controls: age, t = −0.86, p = 0.4; sex, χ2 = 0.51, p = 0.48). Baseline PGC-1α levels were significantly lower in patients with unipolar (n = 54; F 1,122 = 5.40, p = 0.02) but not bipolar (n = 13; F 1,81 = 0.28, p = 0.60) depression compared with controls (n = 70) (Fig. 2a). Adjusting for potential covariates did not alter the results (unipolar depressed: F 1,118 = 4.24, p = 0.04; bipolar depressed: F 1,77 = 1.08, p = 0.30).

Fig. 2. PGC-1α mRNA levels are lower in patients with unipolar and psychotic depression compared with controls. (a) PGC-1α mRNA levels were significantly lower in patients with unipolar depression (n = 54) at baseline compared with controls (n = 70). There was no significant difference in PGC-1α mRNA levels in blood from patients with bipolar depression (n = 13) compared with controls or patients with unipolar depression. (b) PGC-1α mRNA levels were significantly lower in patients with psychotic depression (n = 16) at baseline compared with controls (n = 70). There was no significant difference in PGC-1α mRNA levels in blood from patients with non-psychotic depression (n = 51) compared with controls or patients with psychotic depression. Data are expressed as unadjusted mean log10RQ ± s.e.m.. *p < 0.05 v. control.

We then assessed PGC-1α mRNA levels in patients with psychotic and non-psychotic depression compared with age- and sex-matched controls (psychotic depressed v. controls: age, t = 1.81, p = 0.08; sex, χ2 = 0.11, p = 0.74; non-psychotic depressed v. controls: age, t = 0.12, p = 0.90; sex, χ2 = 0.03, p = 0.86). Baseline PGC-1α levels were significantly lower in patients with psychotic (n = 16; F 1,84 = 4.99, p = 0.03) but not non-psychotic (n = 51; F 1,119 = 2.73, p = 0.10) depression compared with controls (n = 70) (Fig. 2b). Adjusting for potential covariates resulted in a trend towards a significant difference in the psychotic depressed group (F 1,80 = 3.89, p = 0.05) but did not alter the result in the non-psychotic depressed group (F 1,115 = 2.91, p = 0.09).

Taking our analyses one step further, we found that patients with psychotic unipolar depression (n = 13) had significantly lower PGC-1α mRNA levels (F 1,81 = 9.05, p = 0.004) compared with age- and sex-matched healthy controls (n = 70; age, t = 1.80, p = 0.08; sex, χ2 = 0.12, p = 0.73; Fig. 3a). Adjusting for potential covariates did not alter the result (F 1,77 = 7.07, p = 0.01). Compared with age- and sex-matched controls (n = 70), we found no significant difference in PGC-1α levels in patients with non-psychotic unipolar depression (n = 41; age, t = 0.63, p = 0.53; sex, χ2 = 0.03, p = 0.87; F 1,109 = 2.20, p = 0.14; Fig. 3a). Adjusting for potential covariates did not alter these results.

Fig. 3. PGC-1α mRNA levels are lower in patients with psychotic unipolar depression and increased by ECT. (a) PGC-1α mRNA levels were significantly lower in patients with psychotic unipolar depression (n = 13) pre-ECT compared with controls (n = 70). There was no significant difference in PGC-1α mRNA levels in blood from patients with non-psychotic unipolar depression (n = 41) compared with controls or patients with psychotic depression. (b) PGC-1α mRNA levels were significantly increased in patients with psychotic but not non-psychotic unipolar depression following treatment with ECT. Data are expressed as unadjusted mean log10RQ ± s.e.m.. *p < 0.05 v. control; +p < 0.05 v. pre-ECT.

ECT increases PGC-1α mRNA levels in patients with psychotic unipolar depression

PGC-1α mRNA levels were initially assessed in samples from patients with depression as a single group (Fig. 1). PGC-1α levels were not significantly altered in patients following treatment with ECT (F 1,66 = 0.09, p = 0.77).

We subsequently investigated PGC-1α levels in depression subtypes pre-/post-ECT, i.e. patients with unipolar/bipolar depression, patients with psychotic/non-psychotic depression, and patients with psychotic v. non-psychotic unipolar depression.

Our patient group consisted of 54 patients with unipolar and 13 patients with bipolar depression (online Supplementary Table S1 for demographics and clinical characteristics). We found no difference in PGC-1α levels between patients with bipolar or unipolar depression pre-/post-ECT, and adjusting for potential covariates did not alter the result (Table 2).

Table 2. Subgroup analyses of PGC-1α mRNA levels based on clinical features

ECT, electroconvulsive therapy.

Data are presented as mean log10RQ (s.e.m.).

We investigated PGC-1α levels in patients with psychotic (n = 16) compared with non-psychotic (n = 51) depression pre-/post-ECT (online Supplementary Table S1 for demographics and clinical characteristics). PGC-1α levels did not differ between patients with psychotic depression and non-psychotic depression pre-/post-treatment, and adjusting for potential covariates did not alter the result (Table 2).

Interestingly, when we examined PGC-1α levels in patients with psychotic v. non-psychotic unipolar depression pre-/post-ECT we found a significant group × time effect (F 1,52 = 4.23, p = 0.045), with levels increased in the psychotic unipolar group following treatment (Fig. 3b; online Supplementary Table S1 for demographics and clinical characteristics). Adjusting for potential covariates did not alter this result (F 1,46 = 5.24, p = 0.027).

ECT laterality does not affect PGC-1α mRNA levels

We assessed PGC-1α mRNA levels in patients treated with high-dose unilateral (n = 35) or bitemporal (n = 32) ECT to determine if the form of ECT administered would result in differences in PGC-1α levels post-treatment (online Supplementary Table S1 for demographics and clinical characteristics). PGC-1α levels did not differ between patients treated with unilateral or bitemporal ECT pre-/post-treatment. Adjusting for potential covariates did not alter the result (Table 2).

PGC-1α mRNA levels are unrelated to response or remission status following ECT

PGC-1α mRNA levels were assessed in samples from ECT responder (n = 42) and non-responder (n = 25) patients (online Supplementary Table S1 for demographics and clinical characteristics). There was no difference in PGC-1α levels between responders and non-responders, and adjusting for potential covariates did not alter the result (Table 2).

PGC-1α mRNA levels were next assessed in ECT remitters (n = 34) and non-remitters (n = 33) (online Supplementary Table S1 for demographics and clinical characteristics). There was no difference in PGC-1α levels in remitters compared with non-remitters, and adjusting for potential covariates did not alter the result (Table 2).

As we found differences in PGC-1α levels in patients with unipolar depression with or without psychosis, we also explored PGC-1α levels in responders/non-responders and remitters/non-remitters in this subgroup. We found no differences in PGC-1α levels using unadjusted or adjusted models (data not shown).

PGC-1α mRNA levels and clinical outcome

We assessed the relationship between PGC-1α mRNA levels and HAM-D24 scores in the patient group as a whole (online Supplementary Table S2). We found no correlation between baseline PGC-1α levels and HAM-D24 scores (r = 0.16, p = 0.19), baseline PGC-1α levels and change in HAM-D24 score (r = 0.04, p = 0.75), or between the change in PGC-1α levels and the change in HAM-D24 score (ρ = 0.04, p = 0.75).

We subsequently examined the relationship between PGC-1α levels and HAM-D24 scores in the unipolar/bipolar depressed groups, psychotic/non-psychotic depressed groups, and the psychotic/non-psychotic unipolar depressed groups using exploratory analyses and found no significant correlation at the p < 0.01 level (online Supplementary Table S2). We also found no correlation between PGC-1α levels and HAM-D24 scores in the bitemporal/unilateral ECT groups, responders/non-responders or in remitters/non-remitters.

Discussion

This is the first study to report on circulating PGC-1α mRNA levels in patients experiencing a major depressive episode compared with healthy controls, and following treatment with ECT. We show that PGC-1α mRNA levels are significantly lower in patients with depression compared with controls, and that this difference survives adjustment for potential covariates. Our exploratory analyses show that these lower PGC-1α mRNA levels occur in patients with unipolar as opposed to bipolar depression, and are most profound in those with psychotic unipolar depression. ECT did not alter PGC-1α mRNA levels in the depressed group as a whole but did increase PGC-1α mRNA levels in the psychotic unipolar depressed group, though levels did not return to those of controls. We found no association between PGC-1α mRNA levels and mood scores.

As outlined in the Introduction, PGC-1α has widespread functions, is found in numerous tissues including the brain, and is required for neurotransmission and synaptic function. Thus, alterations in PGC-1α could lead to widespread deleterious effects. Importantly, decreased PGC-1α may represent a common link between the various pathophysiological processes implicated in depression, including inflammation, neurogenesis, circadian rhythm disruption and alterations in mitochondrial respiration (Fig. 4).

Fig. 4. Links between factors leading to lower PGC-1α mRNA levels and the association with pathophysiological processes implicated in depression.

PGC-1α is regulated by sirtuin-1 (SIRT-1), levels of which are reportedly decreased in patients with depression (Abe et al., Reference Abe, Uchida, Otsuki, Hobara, Yamagata, Higuchi, Shibata and Watanabe2011; Luo and Zhang, Reference Luo and Zhang2016). In mammals, SIRT-1 regulates PGC-1α transcriptional activity via deacetylation at specific lysine residues in an NAD(+)-dependent manner (Rodgers et al., Reference Rodgers, Lerin, Haas, Gygi, Spiegelman and Puigserver2005), leading to increased transcriptional activity and target gene activation (Rodgers et al., Reference Rodgers, Lerin, Haas, Gygi, Spiegelman and Puigserver2005; Lin et al., Reference Lin, Liu and Li2008). SIRT-1 overexpression drives an increase in PGC-1α in neuronal cells, which suggests high coupling of these two proteins (Chang and Guarente, Reference Chang and Guarente2013). We have recently shown that SIRT-1 is one of three shared targets of the microRNAs miR-126-3p and miR-106a-5p, both of which have been implicated in psychotic depression (Kolshus et al., Reference Kolshus, Ryan, Blackshields, Smyth, Sheils and McLoughlin2017), and that blood SIRT1 mRNA levels are significantly lower in patients with depression compared with controls (unpublished observations). Moreover, we and others have shown that VEGFA, another shared target of these microRNAs, is altered in depression (Carvalho et al., Reference Carvalho, Kohler, McIntyre, Knochel, Brunoni, Thase, Quevedo, Fernandes and Berk2015; Kolshus et al., Reference Kolshus, Ryan, Blackshields, Smyth, Sheils and McLoughlin2017) and PGC-1α has previously been implicated in VEGFA regulation (Arany et al., Reference Arany, Foo, Ma, Ruas, Bommi-Reddy, Girnun, Cooper, Laznik, Chinsomboon, Rangwala, Baek, Rosenzweig and Spiegelman2008). Of note, we have shown that protein levels of the neurotrophin pigment epithelium-derived neurotrophic factor (PEDF), which can also regulate VEGFA, are increased in patients with depression and levels are augmented by treatment with ECT (Ryan et al., Reference Ryan, Glaviano, O'Donovan, Kolshus, Dunne, Kavanagh, Jelovac, Noone, Tucker, Dunn and McLoughlin2017).

A dysregulated immune response is often observed in patients with depression, with increased levels of the pro-inflammatory cytokines tumour necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and IL-1β reported (Howren et al., Reference Howren, Lamkin and Suls2009; Dowlati et al., Reference Dowlati, Herrmann, Swardfager, Liu, Sham, Reim and Lanctot2010), with ECT reported to induce changes in the levels of these cytokines (Jarventausta et al., Reference Jarventausta, Sorri, Kampman, Bjorkqvist, Tuohimaa, Hamalainen, Moilanen, Leinonen, Peltola and Lehtimaki2017; Yrondi et al., Reference Yrondi, Sporer, Peran, Schmitt, Arbus and Sauvaget2018). Of note, TNF-α and IL-1α, but not IL-6, decrease PGC-1α mRNA levels in liver cells in vitro and in vivo (Kim et al., Reference Kim, Sweeney, Shigenaga, Chui, Moser, Grunfeld and Feingold2007). PGC-1α has also been shown to down-regulate several pro-inflammatory cytokines, and up-regulate mRNA and protein levels of the anti-inflammatory mediator IL-1 receptor antagonist (IL-1ra) (Buler et al., Reference Buler, Aatsinki, Skoumal, Komka, Toth, Kerkela, Georgiadi, Kersten and Hakkol2012), an antagonist of the IL-1 receptor 1 through which IL-1β signals (Garlanda et al., Reference Garlanda, Dinarello and Mantovani2013). The PGC-1α-induced increase in IL-1ra in turn suppresses acute phase proteins, e.g. C-reactive protein and haptoglobin, provoked by IL-1β (Buler et al., Reference Buler, Aatsinki, Skoumal, Komka, Toth, Kerkela, Georgiadi, Kersten and Hakkol2012). Moreover, PGC-1α can reduce human astrocytic IL-6 production under both normal and inflammatory conditions, and PGC-1α overexpression in astrocytes also reduces ROS production and resistance to ROS-induced cell death following exposure to an oxidative insult (Nijland et al., Reference Nijland, Witte, van het Hof, van der Pol, Bauer, Lassmann, van der Valk, de Vries and van Horssen2014). Importantly, when neurons are co-cultured with astrocytes overexpressing PGC-1α they are protected against oxidative insult (Nijland et al., Reference Nijland, Witte, van het Hof, van der Pol, Bauer, Lassmann, van der Valk, de Vries and van Horssen2014). Hence, the increased levels of inflammation observed in patients with depression may be responsible for the low PGC-1α mRNA levels. Conversely, low PGC-1α levels may occur owing to other as yet unidentified mechanisms that in turn could lead to the increased inflammatory tone observed in depression.

As mentioned, PGC-1α may exert beneficial effects via the kynurenine pathway, the main pathway involved in peripheral metabolism of the amino acid tryptophan (Harkin, Reference Harkin2014). Disturbed tryptophan metabolism and dysregulation of the kynurenine pathway have been noted in depression, with decreased levels of kynurenine and kynurenic acid and increased levels of quinolinic acid observed in patients with depression compared with controls (Ogyu et al., Reference Ogyu, Kubo, Noda, Iwata, Tsugawa, Omura, Wada, Tarumi, Plitman, Moriguchi, Miyazaki, Uchida, Graff-Guerrero, Mimura and Nakajima2018). In animals, PGC-1α overexpression has been shown to increase peripheral expression of KATs and enhance the peripheral metabolism of kynurenine to kynurenic acid (Agudelo et al., Reference Agudelo, Femenia, Orhan, Porsmyr-Palmertz, Goiny, Martinez-Redondo, Correia, Izadi, Bhat, Schuppe-Koistinen, Pettersson, Ferreira, Krook, Barres, Zierath, Erhardt, Lindskog and Ruas2014). This has been suggested as a mechanism by which PGC-1α limits availability of kynurenine to the brain where it can be converted to neurotoxic metabolites like quinolinic acid (Harkin, Reference Harkin2014). Notably, ECT has been shown to increase serum levels of kynurenic acid and cause a shift in tryptophan–kynurenine pathway metabolites towards those with neuroprotective properties (n = 19 patients with unipolar or bipolar depression), which correlates with the antidepressant effects of ECT (Guloksuz et al., Reference Guloksuz, Arts, Walter, Drukker, Rodriguez, Myint, Schwarz, Ponds, van Os, Kenis and Rutten2015). In contrast, Schwieler et al. (Reference Schwieler, Samuelsson, Frye, Bhat, Schuppe-Koistinen, Jungholm, Johansson, Landen, Sellgren and Erhardt2016) reported that ECT does not affect plasma levels of kynurenic acid (n = 18 patients with major depressive disorder), though ECT was again found to cause a shift in tryptophan–kynurenine pathway metabolites towards those that are neuroprotective. Both of these studies included patient groups with small sample numbers. Thus, further studies of larger patient groups are required to determine the contribution of the PGC-1α/kynurenine pathway to depression and response to ECT.

Circadian rhythm and Clock gene disturbances are known to be associated with depression (Schuch et al., Reference Schuch, Genro, Bastos, Ghisleni and Tovo-Rodrigues2017; Zaki et al., Reference Zaki, Spence, BaHammam, Pandi-Perumal, Cardinali and Brown2017). Interestingly, PGC-1α plays a key role in linking the clock and metabolic pathways (Lin et al., Reference Lin, Liu and Li2008). PGC-1α displays diurnal variation and is itself regulated by circadian cues, such as light and nutritional status. It also stimulates core clock gene expression, including Bmal1, Clock and Rev-erb factors (Lin et al., Reference Lin, Liu and Li2008), via co-activation of RAR-related orphan receptor-a (RORA) (Geoffroy et al., Reference Geoffroy, Etain, Lajnef, Zerdazi, Brichant-Petitjean, Heilbronner, Hou, Degenhardt, Rietschel, McMahon, Schulze, Jamain, Marie-Claire and Bellivier2016). Thus, PGC-1α dysregulation could lead to the circadian rhythm alterations observed in depression.

In this study, PGC-1α mRNA levels were not altered by ECT in all patients. As mentioned earlier, patients recruited into the EFFECT-Dep trial were receiving treatment with pharmacotherapy as usual. The PGC-1α/PPARGC1A gene has previously been linked to the response to lithium in two independent Caucasian samples of bipolar disorder, though the association did not survive Bonferroni correction (Geoffroy et al., Reference Geoffroy, Etain, Lajnef, Zerdazi, Brichant-Petitjean, Heilbronner, Hou, Degenhardt, Rietschel, McMahon, Schulze, Jamain, Marie-Claire and Bellivier2016). Additionally, the selective serotonin reuptake inhibitor (SSRI) paroxetine can increase mitochondrial biogenesis with a concomitant increase in PGC-1α mRNA in vitro (Jeong et al., Reference Jeong, Park, Yoon, Kim, Lee, Lee, Namkoong and Kim2015). We found no association between PGC-1α levels and treatment with either lithium or paroxetine here (data not shown).

There are some limitations to our study. Firstly, all patients were receiving pharmacotherapy as usual. As EFFECT-Dep was a real-world trial, we had no patients who had undergone a drug washout period or who were drug-naïve and so were unable to establish whether our findings represent an antidepressant effect rather than a depression-related effect. Future studies should examine PGC-1α levels in antidepressant-naïve patients to determine whether our findings indeed represent a marker of depression. Secondly, we were only able to examine PGC-1α levels in peripheral blood, which may not be reflective of brain levels. Thus, further studies should examine PGC-1α in post-mortem brain tissue and cerebrospinal fluid. While PGC-1α may represent a new therapeutic target for depression, caution must be warranted regarding the use of drugs that might increase PGC-1α levels since high PGC-1α levels can have detrimental effects on the brain and have been shown to induce dopaminergic neuron loss (Ciron et al., Reference Ciron, Lengacher, Dusonchet, Aebischer and Schneider2012; Clark et al., Reference Clark, Silvaggi, Kiselak, Zheng, Clore, Dai, Bass and Simon2012). Thirdly, we only assessed PGC-1α mRNA levels and not protein here. Thus, it is unknown at present if the changes we observed at the mRNA level are also reflected at a functional level. This will be addressed by future studies. Fourthly, in this study we assessed PGC-1α levels at 1–3 days post-ECT and so we may have missed changes in PGC-1α levels following ECT. Thus, a time-course study is warranted to determine the temporal profile of PGC-1a post-ECT to define the optimal time-point for its measurement.

Ultimately, PGC-1α appears to represent a common link between the various pathophysiological processes implicated in depression. Thus, PGC-1α may represent a novel therapeutic target for treating mood disorders.

Supplementary material

The supplementary material for this article can be found at https://doi.org/10.1017/S0033291718002556.

Acknowledgements

The authors thank the patients and controls for participating in this study.

Financial support

This work was supported by the Health Research Board (HRB), Ireland (TRA/2007/5, HPF/2010/17).

Conflict of interest

D.M. McLoughlin has received a speaker's honorarium from MECTA. K.M. Ryan and I. Patterson have no conflicts of interest to declare.

References

Abe, N, Uchida, S, Otsuki, K, Hobara, T, Yamagata, H, Higuchi, F, Shibata, T and Watanabe, Y (2011) Altered sirtuin deacetylase gene expression in patients with a mood disorder. Journal of Psychiatric Research 45, 11061112.Google Scholar
Agudelo, LZ, Femenia, T, Orhan, F, Porsmyr-Palmertz, M, Goiny, M, Martinez-Redondo, V, Correia, JC, Izadi, M, Bhat, M, Schuppe-Koistinen, I, Pettersson, AT, Ferreira, DMS, Krook, A, Barres, R, Zierath, JR, Erhardt, S, Lindskog, M and Ruas, JL (2014) Skeletal muscle PGC-1alpha1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell 159, 3345.Google Scholar
Aguirre-Rueda, D, Guerra-Ojeda, S, Aldasoro, M, Iradi, A, Obrador, E, Ortega, A, Mauricio, MD, Vila, JM and Valles, SL (2015) Astrocytes protect neurons from Abeta1-42 peptide-induced neurotoxicity increasing TFAM and PGC-1 and decreasing PPAR-gamma and SIRT-1. International Journal of Medical Sciences 12, 4856.Google Scholar
Als, TD, Dahl, HA, Flint, TJ, Wang, AG, Vang, M, Mors, O, Kruse, TA and Ewald, H (2004) Possible evidence for a common risk locus for bipolar affective disorder and schizophrenia on chromosome 4p16 in patients from the Faroe Islands. Molecular Psychiatry 9, 9398.Google Scholar
Arany, Z, Foo, SY, Ma, Y, Ruas, JL, Bommi-Reddy, A, Girnun, G, Cooper, M, Laznik, D, Chinsomboon, J, Rangwala, SM, Baek, KH, Rosenzweig, A and Spiegelman, BM (2008) HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 451, 10081012.Google Scholar
Beckham, EE and Leber, WR (1985) Hamilton Rating Scale for Depression, ECDEU Version Used in the Treatment of Depression Collaborative Research Program. Homewood: The Dorsey Press.Google Scholar
Berlim, MT, Van den Eynde, F and Daskalakis, ZJ (2013) Efficacy and acceptability of high frequency repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for major depression: a systematic review and meta-analysis of randomized trials. Depression and Anxiety 30, 614623.Google Scholar
Blackwood, DH, He, L, Morris, SW, McLean, A, Whitton, C, Thomson, M, Walker, MT, Woodburn, K, Sharp, CM, Wright, AF, Shibasaki, Y, St Clair, DM, Porteous, DJ and Muir, WJ (1996) A locus for bipolar affective disorder on chromosome 4p. Nature Genetics 12, 427430.Google Scholar
Buler, M, Aatsinki, SM, Skoumal, R, Komka, Z, Toth, M, Kerkela, R, Georgiadi, A, Kersten, S and Hakkol, J (2012) Energy-sensing factors coactivator peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha) and AMP-activated protein kinase control expression of inflammatory mediators in liver: induction of interleukin 1 receptor antagonist. Journal of Biological Chemistry 287, 18471860.Google Scholar
Burigo, M, Roza, CA, Bassani, C, Fagundes, DA, Rezin, GT, Feier, G, Dal-Pizzol, F, Quevedo, J and Streck, EL (2006) Effect of electroconvulsive shock on mitochondrial respiratory chain in rat brain. Neurochemical Research 31, 13751379.Google Scholar
Carvalho, AF, Kohler, CA, McIntyre, RS, Knochel, C, Brunoni, AR, Thase, ME, Quevedo, J, Fernandes, BS and Berk, M (2015) Peripheral vascular endothelial growth factor as a novel depression biomarker: a meta-analysis. Psychoneuroendocrinology 62, 1826.Google Scholar
Chang, HC and Guarente, L (2013) SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell 153, 14481460.Google Scholar
Chang, CC, Jou, SH, Lin, TT, Lai, TJ and Liu, CS (2015) Mitochondria DNA change and oxidative damage in clinically stable patients with major depressive disorder. PLoS One 10, e0125855.Google Scholar
Christoforou, A, Le Hellard, S, Thomson, PA, Morris, SW, Tenesa, A, Pickard, BS, Wray, NR, Muir, WJ, Blackwood, DH, Porteous, DJ and Evans, KL (2007) Association analysis of the chromosome 4p15-p16 candidate region for bipolar disorder and schizophrenia. Molecular Psychiatry 12, 10111025.Google Scholar
Ciron, C, Lengacher, S, Dusonchet, J, Aebischer, P and Schneider, BL (2012) Sustained expression of PGC-1alpha in the rat nigrostriatal system selectively impairs dopaminergic function. Human Molecular Genetics 21, 18611876.Google Scholar
Clark, J, Reddy, S, Zheng, K, Betensky, RA and Simon, DK (2011) Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease. BMC Medical Genetics 12, 69.Google Scholar
Clark, J, Silvaggi, JM, Kiselak, T, Zheng, K, Clore, EL, Dai, Y, Bass, CE and Simon, DK (2012) Pgc-1alpha overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf. PLoS One 7, e48925.Google Scholar
Cobb, JA, O'Neill, K, Milner, J, Mahajan, GJ, Lawrence, TJ, May, WL, Miguel-Hidalgo, J, Rajkowska, G and Stockmeier, CA (2016) Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder. Neuroscience 316, 209220.Google Scholar
Coppen, A (1967) The biochemistry of affective disorders. British Journal of Psychiatry 113, 12371264.Google Scholar
Cowell, RM, Blake, KR and Russell, JW (2007) Localization of the transcriptional coactivator PGC-1alpha to GABAergic neurons during maturation of the rat brain. Journal of Comparative Neurology 502, 118.Google Scholar
Dougherty, SE, Bartley, AF, Lucas, EK, Hablitz, JJ, Dobrunz, LE and Cowell, RM (2014) Mice lacking the transcriptional coactivator PGC-1alpha exhibit alterations in inhibitory synaptic transmission in the motor cortex. Neuroscience 271, 137148.Google Scholar
Dowlati, Y, Herrmann, N, Swardfager, W, Liu, H, Sham, L, Reim, EK and Lanctot, KL (2010) A meta-analysis of cytokines in major depression. Biological Psychiatry 67, 446457.Google Scholar
Duman, RS and Vaidya, VA (1998) Molecular and cellular actions of chronic electroconvulsive seizures. Journal of ECT 14, 181193.Google Scholar
Esterbauer, H, Oberkofler, H, Krempler, F and Patsch, W (1999) Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression. Genomics 62, 98102.Google Scholar
Fernandez-Marcos, PJ and Auwerx, J (2011) Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis. The American Journal of Clinical Nutrition 93, 884S890S.Google Scholar
First, M, Spitzer, R, Gibbon, M and Williams, J (1996) Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press.Google Scholar
Friedrich, MJ (2017) Depression is the leading cause of disability around the world. JAMA 317, 1517.Google Scholar
Gardner, A and Boles, RG (2011) Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Progress in Neuropsychopharmacology and Biological Psychiatry 35, 730743.Google Scholar
Garlanda, C, Dinarello, CA and Mantovani, A (2013) The interleukin-1 family: back to the future. Immunity 39, 10031018.Google Scholar
Geoffroy, PA, Etain, B, Lajnef, M, Zerdazi, EH, Brichant-Petitjean, C, Heilbronner, U, Hou, L, Degenhardt, F, Rietschel, M, McMahon, FJ, Schulze, TG, Jamain, S, Marie-Claire, C and Bellivier, F (2016) Circadian genes and lithium response in bipolar disorders: associations with PPARGC1A (PGC-1alpha) and RORA. Genes, Brain and Behavior 15, 660668.Google Scholar
Glombik, K, Stachowicz, A, Slusarczyk, J, Trojan, E, Budziszewska, B, Suski, M, Kubera, M, Lason, W, Wedzony, K, Olszanecki, R and Basta-Kaim, A (2015) Maternal stress predicts altered biogenesis and the profile of mitochondrial proteins in the frontal cortex and hippocampus of adult offspring rats. Psychoneuroendocrinology 60, 151162.Google Scholar
Guloksuz, S, Arts, B, Walter, S, Drukker, M, Rodriguez, L, Myint, AM, Schwarz, MJ, Ponds, R, van Os, J, Kenis, G and Rutten, BP (2015) The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway. Brain Behaviour and Immunity 48, 4852.Google Scholar
Harkin, A (2014) Muscling in on depression. New England Journal of Medicine 371, 23332334.Google Scholar
Howren, MB, Lamkin, DM and Suls, J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine 71, 171186.Google Scholar
Jang, WG, Kim, EJ, Park, KG, Park, YB, Choi, HS, Kim, HJ, Kim, YD, Kim, KS, Lee, KU and Lee, IK (2007) Glucocorticoid receptor mediated repression of human insulin gene expression is regulated by PGC-1alpha. Biochemical and Biophysical Research Communication 352, 716721.Google Scholar
Jarventausta, K, Sorri, A, Kampman, O, Bjorkqvist, M, Tuohimaa, K, Hamalainen, M, Moilanen, E, Leinonen, E, Peltola, J and Lehtimaki, K (2017) Changes in interleukin-6 levels during electroconvulsive therapy may reflect the therapeutic response in major depression. Acta Psychiatrica Scandinavica 135, 8792.Google Scholar
Jeong, J, Park, M, Yoon, JS, Kim, H, Lee, SK, Lee, E, Namkoong, K and Kim, E (2015) Requirement of AMPK activation for neuronal metabolic-enhancing effects of antidepressant paroxetine. Neuroreport 26, 424428.Google Scholar
Jiang, H, Kang, SU, Zhang, S, Karuppagounder, S, Xu, J, Lee, YK, Kang, BG, Lee, Y, Zhang, J, Pletnikova, O, Troncoso, JC, Pirooznia, S, Andrabi, SA, Dawson, VL and Dawson, TM (2016) Adult conditional knockout of PGC-1alpha leads to loss of dopamine neurons. eNeuro 3(4), e0183-16.2016 1–8.Google Scholar
Kang, HJ, Voleti, B, Hajszan, T, Rajkowska, G, Stockmeier, CA, Licznerski, P, Lepack, A, Majik, MS, Jeong, LS, Banasr, M, Son, H and Duman, RS (2012) Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nature Medicine 18, 14131417.Google Scholar
Karabatsiakis, A, Bock, C, Salinas-Manrique, J, Kolassa, S, Calzia, E, Dietrich, DE and Kolassa, IT (2014) Mitochondrial respiration in peripheral blood mononuclear cells correlates with depressive subsymptoms and severity of major depression. Translational Psychiatry 4, e397.Google Scholar
Kato, N (2009) Neurophysiological mechanisms of electroconvulsive therapy for depression. Neuroscience Research 64, 311.Google Scholar
Kendler, KS, Neale, MC, MacLean, CJ, Heath, AC, Eaves, LJ and Kessler, RC (1993) Smoking and major depression. A causal analysis. Archives of General Psychiatry 50, 3643.Google Scholar
Khalaj, L, Nejad, SC, Mohammadi, M, Zadeh, SS, Pour, MH, Ahmadiani, A, Khodagholi, F, Ashabi, G, Alamdary, SZ and Samami, E (2013) Gemfibrozil pretreatment proved protection against acute restraint stress-induced changes in the male rats' hippocampus. Brain Research 1527, 117130.Google Scholar
Kim, MS, Sweeney, TR, Shigenaga, JK, Chui, LG, Moser, A, Grunfeld, C and Feingold, KR (2007) Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells. Metabolism 56, 267279.Google Scholar
Kim, SH, Koh, JH, Higashida, K, Jung, SR, Holloszy, JO and Han, DH (2015) PGC-1alpha mediates a rapid, exercise-induced downregulation of glycogenolysis in rat skeletal muscle. The Journal of Physiology 593, 635643.Google Scholar
Klinedinst, NJ and Regenold, WT (2015) A mitochondrial bioenergetic basis of depression. Journal of Bioenergetics and Biomembranes 47, 155171.Google Scholar
Kolshus, E, Ryan, KM, Blackshields, G, Smyth, P, Sheils, O and McLoughlin, DM (2017) Peripheral blood microRNA and VEGFA mRNA changes following electroconvulsive therapy: implications for psychotic depression. Acta Psychiatrica Scandinavica 136, 594606.Google Scholar
Labuzek, K, Liber, S, Gabryel, B and Okopien, B (2010) AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) increases the production of toxic molecules and affects the profile of cytokines release in LPS-stimulated rat primary microglial cultures. Neurotoxicology 31, 134146.Google Scholar
Liang, H and Ward, WF (2006) PGC-1alpha: a key regulator of energy metabolism. Advances in Physiology Education 30, 145151.Google Scholar
Lin, PY and Tseng, PT (2015) Decreased glial cell line-derived neurotrophic factor levels in patients with depression: a meta-analytic study. Journal of Psychiatric Research 63, 2027.Google Scholar
Lin, J, Wu, PH, Tarr, PT, Lindenberg, KS, St-Pierre, J, Zhang, CY, Mootha, VK, Jager, S, Vianna, CR, Reznick, RM, Cui, L, Manieri, M, Donovan, MX, Wu, Z, Cooper, MP, Fan, MC, Rohas, LM, Zavacki, AM, Cinti, S, Shulman, GI, Lowell, BB, Krainc, D and Spiegelman, BM (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119, 121135.Google Scholar
Lin, JD, Liu, C and Li, S (2008) Integration of energy metabolism and the mammalian clock. Cell Cycle 7, 453457.Google Scholar
Livak, KJ and Schmittgen, TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402408.Google Scholar
Luo, XJ and Zhang, C (2016) Down-regulation of SIRT1 gene expression in major depressive disorder. The American Journal of Psychiatry 173, 1046.Google Scholar
Mootha, VK, Lindgren, CM, Eriksson, KF, Subramanian, A, Sihag, S, Lehar, J, Puigserver, P, Carlsson, E, Ridderstrale, M, Laurila, E, Houstis, N, Daly, MJ, Patterson, N, Mesirov, JP, Golub, TR, Tamayo, P, Spiegelman, B, Lander, ES, Hirschhorn, JN, Altshuler, D and Groop, LC (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genetics 34, 267273.Google Scholar
Muller, N and Schwarz, MJ (2007) The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Molecular Psychiatry 12, 9881000.Google Scholar
Nierenberg, AA, Ghaznavi, SA, Mathias, IS, Ellard, KK, Janos, JA and Sylvia, LG (2018) Peroxisome proliferator activated receptor gamma co-activator-1 alpha as a novel target for bipolar disorder and other neuropsychiatric disorders. Biological Psychiatry 83, 761769.Google Scholar
Nijland, PG, Witte, ME, van het Hof, B, van der Pol, S, Bauer, J, Lassmann, H, van der Valk, P, de Vries, HE and van Horssen, J (2014) Astroglial PGC-1alpha increases mitochondrial antioxidant capacity and suppresses inflammation: implications for multiple sclerosis. Acta Neuropathologica Communications 2, 170.Google Scholar
Ogyu, K, Kubo, K, Noda, Y, Iwata, Y, Tsugawa, S, Omura, Y, Wada, M, Tarumi, R, Plitman, E, Moriguchi, S, Miyazaki, T, Uchida, H, Graff-Guerrero, A, Mimura, M and Nakajima, S (2018) Kynurenine pathway in depression: a systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews 90, 1625.Google Scholar
Polyakova, M, Schroeter, ML, Elzinga, BM, Holiga, S, Schoenknecht, P, de Kloet, ER and Molendijk, ML (2015) Brain-derived neurotrophic factor and antidepressive effect of electroconvulsive therapy: systematic review and meta-analyses of the preclinical and clinical literature. PLoS One 10, e0141564.Google Scholar
Puigserver, P, Wu, Z, Park, CW, Graves, R, Wright, M and Spiegelman, BM (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92, 829839.Google Scholar
Puigserver, P, Rhee, J, Donovan, J, Walkey, CJ, Yoon, JC, Oriente, F, Kitamura, Y, Altomonte, J, Dong, H, Accili, D and Spiegelman, BM (2003) Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 423, 550555.Google Scholar
Qin, W, Haroutunian, V, Katsel, P, Cardozo, CP, Ho, L, Buxbaum, JD and Pasinetti, GM (2009) PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Archives of Neurology 66, 352361.Google Scholar
Rodgers, JT, Lerin, C, Haas, W, Gygi, SP, Spiegelman, BM and Puigserver, P (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434, 113118.Google Scholar
Ryan, KM, Glaviano, A, O'Donovan, SM, Kolshus, E, Dunne, R, Kavanagh, A, Jelovac, A, Noone, M, Tucker, GM, Dunn, MJ and McLoughlin, DM (2017) Electroconvulsive therapy modulates plasma pigment epithelium-derived factor in depression: a proteomics study. Translational Psychiatry 7, e1073.Google Scholar
Rytinki, MM and Palvimo, JJ (2009) SUMOylation attenuates the function of PGC-1alpha. The Journal of Biological Chemistry 284, 2618426193.Google Scholar
Sajan, MP, Ivey, RA and Farese, RV (2015) BMI-related progression of atypical PKC-dependent aberrations in insulin signaling through IRS-1, Akt, FoxO1 and PGC-1alpha in livers of obese and type 2 diabetic humans. Metabolism 64, 14541465.Google Scholar
Schosser, A, Gaysina, D, Cohen-Woods, S, Domenici, E, Perry, J, Tozzi, F, Korszun, A, Gunasinghe, C, Gray, J, Jones, L, Binder, EB, Holsboer, F, Craddock, N, Owen, MJ, Craig, IW, Farmer, AE, Muglia, P and McGuffin, P (2011) A follow-up case-control association study of tractable (druggable) genes in recurrent major depression. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 156B, 640650.Google Scholar
Schuch, JB, Genro, JP, Bastos, CR, Ghisleni, G and Tovo-Rodrigues, L (2017) The role of CLOCK gene in psychiatric disorders: evidence from human and animal research. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 177, 181198.Google Scholar
Schwieler, L, Samuelsson, M, Frye, MA, Bhat, M, Schuppe-Koistinen, I, Jungholm, O, Johansson, AG, Landen, M, Sellgren, CM and Erhardt, S (2016) Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients. Journal of Neuroinflammation 13, 51.Google Scholar
Semkovska, M, Landau, S, Dunne, R, Kolshus, E, Kavanagh, A, Jelovac, A, Noone, M, Carton, M, Lambe, S, McHugh, C and McLoughlin, DM (2016) Bitemporal versus high-dose unilateral twice-weekly electroconvulsive therapy for depression (EFFECT-Dep): a pragmatic, randomized, non-inferiority trial. The American Journal of Psychiatry 173, 408417.Google Scholar
Simon, GE, Von Korff, M, Saunders, K, Miglioretti, DL, Crane, PK, van Belle, G and Kessler, RC (2006) Association between obesity and psychiatric disorders in the US adult population. Archives of General Psychiatry 63, 824830.Google Scholar
Soyal, SM, Felder, TK, Auer, S, Hahne, P, Oberkofler, H, Witting, A, Paulmichl, M, Landwehrmeyer, GB, Weydt, P, Patsch, W and European Huntington Disease Network (2012) A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset. Human Molecular Genetics 21, 34613473.Google Scholar
St-Pierre, J, Drori, S, Uldry, M, Silvaggi, JM, Rhee, J, Jager, S, Handschin, C, Zheng, K, Lin, J, Yang, W, Simon, DK, Bachoo, R and Spiegelman, BM (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127, 397408.Google Scholar
Sugden, MC, Caton, PW and Holness, MJ (2010) PPAR control: it's SIRTainly as easy as PGC. Journal of Endocrinology 204, 93104.Google Scholar
Takacs, M, Petoukhov, MV, Atkinson, RA, Roblin, P, Ogi, FX, Demeler, B, Potier, N, Chebaro, Y, Dejaegere, A, Svergun, DI, Moras, D and Billas, IM (2013) The asymmetric binding of PGC-1alpha to the ERRalpha and ERRgamma nuclear receptor homodimers involves a similar recognition mechanism. PLoS One 8, e67810.Google Scholar
Tang, K, Wagner, PD and Breen, EC (2010) TNF-alpha-mediated reduction in PGC-1alpha may impair skeletal muscle function after cigarette smoke exposure. Journal of Cellular Physiology 222, 320327.Google Scholar
Thau, N, Knippenberg, S, Korner, S, Rath, KJ, Dengler, R and Petri, S (2012) Decreased mRNA expression of PGC-1alpha and PGC-1alpha-regulated factors in the SOD1G93A ALS mouse model and in human sporadic ALS. Journal of Neuropathology and Experimental Neurology 71, 10641074.Google Scholar
Tritos, NA, Mastaitis, JW, Kokkotou, EG, Puigserver, P, Spiegelman, BM and Maratos-Flier, E (2003) Characterization of the peroxisome proliferator activated receptor coactivator 1 alpha (PGC 1alpha) expression in the murine brain. Brain Research 961, 255260.Google Scholar
Tseng, PT, Cheng, YS, Chen, YW, Wu, CK and Lin, PY (2015) Increased levels of vascular endothelial growth factor in patients with major depressive disorder: a meta-analysis. European Neuropsychopharmacology 25, 16221630.Google Scholar
UK ECT Review Group (2003) Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361, 799808.Google Scholar
Vega, RB, Huss, JM and Kelly, DP (2000) The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Molecular and Cellular Biology 20, 18681876.Google Scholar
Villena, JA (2015) New insights into PGC-1 coactivators: redefining their role in the regulation of mitochondrial function and beyond. The FEBS Journal 282, 647672.Google Scholar
Wang, Q and Dwivedi, Y (2017) Transcriptional profiling of mitochondria associated genes in prefrontal cortex of subjects with major depressive disorder. The World Journal of Biological Psychiatry 18, 592603.Google Scholar
Weydt, P, Soyal, SM, Landwehrmeyer, GB, Patsch, W and European Huntington Disease Network (2014) A single nucleotide polymorphism in the coding region of PGC-1alpha is a male-specific modifier of Huntington disease age-at-onset in a large European cohort. BMC Neurology 14, 1.Google Scholar
World Health Organisation (2017) Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organisation. Available at http://apps.who.int/iris/bitstream/10665/254610/1/WHO-MSD-MER-2017.2-eng.pdf?ua=1.Google Scholar
World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310, 21912194.Google Scholar
Yrondi, A, Sporer, M, Peran, P, Schmitt, L, Arbus, C and Sauvaget, A (2018) Electroconvulsive therapy, depression, the immune system and inflammation: a systematic review. Brain Stimulation 11, 2951.Google Scholar
Zaki, NFW, Spence, DW, BaHammam, AS, Pandi-Perumal, SR, Cardinali, DP and Brown, GM (2017) Chronobiological theories of mood disorder. European Archives of Psychiatry and Clinical Neuroscience 268, 107118.Google Scholar
Figure 0

Table 1. Demographic and clinical characteristics of participants

Figure 1

Fig. 1. PGC-1α mRNA levels are lower in patients with depression compared with controls but are unaltered by ECT. PGC-1α mRNA levels were significantly lower in patients with depression at baseline, i.e. pre-ECT (n = 67), compared with controls (n = 70). PGC-1α mRNA levels were unaltered in patients with depression following treatment with ECT. Data are expressed as unadjusted mean log10RQ ± s.e.m.. *p < 0.05 v. control.

Figure 2

Fig. 2. PGC-1α mRNA levels are lower in patients with unipolar and psychotic depression compared with controls. (a) PGC-1α mRNA levels were significantly lower in patients with unipolar depression (n = 54) at baseline compared with controls (n = 70). There was no significant difference in PGC-1α mRNA levels in blood from patients with bipolar depression (n = 13) compared with controls or patients with unipolar depression. (b) PGC-1α mRNA levels were significantly lower in patients with psychotic depression (n = 16) at baseline compared with controls (n = 70). There was no significant difference in PGC-1α mRNA levels in blood from patients with non-psychotic depression (n = 51) compared with controls or patients with psychotic depression. Data are expressed as unadjusted mean log10RQ ± s.e.m.. *p < 0.05 v. control.

Figure 3

Fig. 3. PGC-1α mRNA levels are lower in patients with psychotic unipolar depression and increased by ECT. (a) PGC-1α mRNA levels were significantly lower in patients with psychotic unipolar depression (n = 13) pre-ECT compared with controls (n = 70). There was no significant difference in PGC-1α mRNA levels in blood from patients with non-psychotic unipolar depression (n = 41) compared with controls or patients with psychotic depression. (b) PGC-1α mRNA levels were significantly increased in patients with psychotic but not non-psychotic unipolar depression following treatment with ECT. Data are expressed as unadjusted mean log10RQ ± s.e.m.. *p < 0.05 v. control; +p < 0.05 v. pre-ECT.

Figure 4

Table 2. Subgroup analyses of PGC-1α mRNA levels based on clinical features

Figure 5

Fig. 4. Links between factors leading to lower PGC-1α mRNA levels and the association with pathophysiological processes implicated in depression.

Supplementary material: File

Ryan supplementary material

Table S1

Download Ryan supplementary material(File)
File 19.6 KB
Supplementary material: File

Ryan supplementary material

Table S2

Download Ryan supplementary material(File)
File 15.5 KB